← All trials
NCT05227833
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2022
- Primary completion
- Nov 15, 2022
- Completion date
- Nov 15, 2022
- First posted
- Feb 7, 2022
- Last posted
- Nov 17, 2022
- Enrollment
- 284
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Alexandria UniversityLead sponsor
- Alexandria UniversityOverall official - principal investigator
- Alexandria UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.